Cullinan Therapeutics, Inc. is a biopharmaceutical company dedicated to creating new standards of care for patients. The company has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, the Cullinan team creates differentiated ideas, identifies the most appropriate targets, and selects the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. The company pushes conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, its team exercises creativity and urgency to deliver on its promise to bring new therapeutic solutions to patients.